Primate erythroparvovirus 1, generally referred to as B19 virus, parvovirus B19 or sometimes erythrovirus B19, was the first (and until 2005 the only) known human virus in the family Parvoviridae, genus Erythroparvovirus; it measures only 23–26 nm in diameter. The name is derived from Latin, parvum meaning small, reflecting the fact that B19 ranks among the smallest DNA viruses. B19 virus is most known for causing disease in the pediatric population; however, it can also affect adults. It is the classic cause of the childhood rash called fifth disease or erythema infectiosum, or "slapped cheek syndrome".
|Primate erythroparvovirus 1|
|Electron micrograph of Parvoviruses in blood|
Primate erythroparvovirus 1
Erythroviruses belong to the Parvoviridae family of small DNA viruses. It is a non-enveloped, icosahedral virus that contains a single-stranded linear DNA genome of approximately 5,600 base pairs in length. The infectious particles may contain either positive or negative strands of DNA. The icosahedral capsid consists of 60 capsomeres, consisting of two structural proteins, VP1 (83 kDa) and VP2 (58 kDa), which are identical except for 227 amino acids at the amino-terminal of the VP1-protein, the so-called VP1-unique region. VP2 is the major capsid protein, and comprises approximately 95% of the total virus particle. VP1-proteins are incorporated into the capsid structure in a non-stoichiometrical relation (based on antibody-binding analysis and X-ray structural analysis the VP1-unique region is assumed to be exposed at the surface of the virus particle. At each end of the DNA molecule there are palindromic sequences which form "hairpin" loops. The hairpin at the 3' end serves as a primer for the DNA polymerase. It is classified as an erythrovirus because of its capability to invade red blood cell precursors in the bone marrow. Three genotypes (with subtypes) have been recognised.
The nucleotide substitution rate for total coding DNA has been estimated to be 1.03 (0.6-1.27) x 10−4 substitutions/site/year. This rate is similar to that of other single stranded DNA viruses. VP2 codons were found to be under purifying selection. In contrast VP1 codons in the unique part of the gene were found to be under diversifying selection. This diversifying selection is consistent with persistent infection as this part of the VP1 protein contains epitopes recognised by the immnune system.
Like other nonenveloped DNA viruses, pathogenicity of parvovirus B19 involves binding to host cell receptors, internalization, translocation of the genome to the host nucleus, DNA replication, RNA transcription, assembly of capsids and packaging of the genome, and finally cell lysis with release of the mature virions. In humans the P antigen (also known as globoside) is the cellular receptor for parvovirus B19 virus that causes erythema infectiosum (fifth disease) in children. This infection is sometimes complicated by severe aplastic anemia caused by lysis of early erythroid precursors.
The most recent common ancestor of the extant strains has been dated to about 12,600 years ago. Three genotypes—1, 2 and 3 -- are recognised. A recombination between types 1 and 3 gave rise to genotype 2 between 5,000 and 6,800 years ago.
The virus is primarily spread by infected respiratory droplets; blood-borne transmission, however, has been reported. The secondary attack risk for exposed household persons is about 50%, and about half of that for classroom contacts.
Symptoms begin some six days after exposure (between 4 and 28 days, with the average being 16 to 17 days) and last about a week. Infected patients with normal immune systems are contagious before becoming symptomatic, but probably not after. Individuals with B19 IgG antibodies are generally considered immune to recurrent infection, but reinfection is possible in a minority of cases. About half of adults are B19-immune due to a past infection.
Parvovirus B19 causes an infection in humans only. Cat and dog parvoviruses do not infect humans. There is no vaccine available for human parvovirus B19, though attempts have been made to develop one.
Role in diseaseEdit
Fifth disease or erythema infectiosum is only one of several expressions of parvovirus B19. The associated bright red rash of the cheeks gives it the nickname "slapped cheek syndrome". Any age may be affected, although it is most common in children aged six to ten years. It is so named because it was the fifth most common cause of a pink-red infection associated rash to be described by physicians (many of the others, such as measles and rubella, are rare now).
Once infected, patients usually develop the illness after an incubation period of four to fourteen days. The disease commences with high fever and malaise, when the virus is most abundant in the bloodstream, and patients are usually no longer infectious once the characteristic rash of this disease has appeared. The following symptoms are characteristic:
- A usual brief viral prodrome with fever, headache, nausea, diarrhea.
- As the fever breaks, a red rash forms on the cheeks, with relative pallor around the mouth ("slapped cheek rash"), sparing the nasolabial folds, forehead, and mouth.
- "Lace-like, (reticular)" red rash on trunk or extremities then follows the facial rash. Infection in adults usually only involves the reticular rash, with multiple joint pain predominating.
- Exacerbation of rash by sunlight, heat, stress.
Teenagers or young adults may develop the so-called "Papular Purpuric Gloves and Socks Syndrome".
Parvovirus B19 is a cause of chronic anemia in individuals who have AIDS. It is frequently overlooked. Treatment with intravenous immunoglobulin usually resolves the anemia although relapse can occur. The parvovirus infection may trigger an inflammatory reaction in AIDS patients who have just begun antiretroviral therapy.
Arthritis and arthralgiasEdit
Arthralgias and arthritis are commonly reported in association with parvovirus B19 infection in adults whereas erythema infectiosum is the main symptom observed in children. The occurrence of arthralgia coincides with the initial detection of circulating IgM- and IgG-antibodies against the viral structural proteins VP1 and VP2. Parvovirus B19 infection may affect the development of arthritis. In adults (and perhaps some children), parvovirus B19 can lead to a seronegative arthritis which is usually easily controlled with analgesics. Women are approximately twice as likely as men to experience arthritis after parvovirus infection. Possibly up to 15% of all new cases of arthritis are due to parvovirus, and a history of recent contact with a patient and positive serology generally confirms the diagnosis. This arthritis does not progress to other forms of arthritis. Typically joint symptoms last 1–3 weeks, but in 10–20% of those affected, it may last weeks to months.
A Danish study has links between B19 with polymyalgia rheumatica.
Although most patients have a decrease of erythropoiesis (production of red blood cells) during parvovirus infection, it is most dangerous in patients with pre-existing bone marrow stress, for example sickle cell anemia or hereditary spherocytosis, and are therefore heavily dependent on erythropoiesis due to the reduced lifespan of the red cells. This is termed "aplastic crisis" (also called reticulocytopenia). It is treated with blood transfusion.
Parvovirus infection in pregnant women is associated with hydrops fetalis due to severe fetal anemia, sometimes leading to miscarriage or stillbirth. This is due to a combination of hemolysis of the red blood cells, as well as the virus directly negatively affecting the red blood cell precursors in the bone marrow. The risk of fetal loss is about 10% if infection occurs before pregnancy week 20 (especially between weeks 14 and 20), but minimal after then. Routine screening of the antenatal sample would enable the pregnant mother to determine the risk of infection. Knowledge of her status would allow the mother to avoid contact with individuals suspected or known to have an ongoing infection, however, at the present time, antenatal testing for immunity is not recommended, since there is no good means to prevent the infection, there is no specific therapy and there are no vaccines available. It may increase maternal anxiety and fear without proven benefit. The best approach would be to recommend all pregnant women to avoid contact with children with current symptoms of infection, as described above. The risk to the fetus will be reduced with correct diagnosis of the anemia (by ultrasound scans) and treatment (by blood transfusions). There is some evidence that intrauterine parvovirus B19 infection leads to developmental abnormalities in childhood.
At the moment, there are no treatments that directly target parvovirus B19 virus. Intravenous immunoglobulin therapy (IVIG) therapy has been a popular alternative because doctors can administer it without stopping chemotherapy drugs like MEL-ASCT. Also, the treatment's side effects are rare as only 4 out of 133 patients had complications (2 had acute kidney injury and 2 had pulmonary edema) even though 69 of the patients had organ transplants and 39 of them were HIV positive. This is a large improvement over administering rituximab. The monoclonal antibody against the CD20 protein has been shown to cause acute hepatitis, neutropenia via parvovirus B19 reactivations, and even persistent parvovirus B19 infection. However, it is important to note that IVIG therapy is not perfect as 34% of treated patients will have a relapse after 4 months.
As of 2017, no approved human vaccine existed against parvovirus B19.
- Servey JT, Reamy BV, Hodge J (February 2007). "Clinical presentations of parvovirus B19 infection". Am Fam Physician. 75 (3): 373–376. PMID 17304869.
- Kahn JS, Kesebir D, Cotmore SF, et al. (July 2008). "Seroepidemiology of human bocavirus defined using recombinant virus-like particles". J. Infect. Dis. 198 (1): 41–50. doi:10.1086/588674. PMID 18491974.
- Heegaard ED, Brown KE (July 2002). "Human parvovirus B19". Clin. Microbiol. Rev. 15 (3): 485–505. doi:10.1128/CMR.15.3.485-505.2002. PMC 118081. PMID 12097253.
- Vafaie J, Schwartz RA (2004). "Parvovirus B19 infections". Int J Dermatol. 43 (10): 747–749. doi:10.1111/j.1365-4632.2004.02413.x. PMID 15485533.
- Sabella C, Goldfarb J (October 1999). "Parvovirus B19 infections". Am Fam Physician. 60 (5): 1455–60. PMID 10524489. Retrieved 6 November 2009.
- Heegaard ED, Brown KE (2002). "Human parvovirus B19". Clin. Microbiol. Rev. 15 (3): 485–505. doi:10.1128/CMR.15.3.485-505.2002. PMC 118081. PMID 12097253.
- Cossart YE, Field AM, Cant B, Widdows D (1975). "Parvovirus-like particles in human sera". Lancet. 1 (7898): 72–73. doi:10.1016/S0140-6736(75)91074-0. PMID 46024. S2CID 33355430.
- Brown KE (2004). "Variants of B19". Dev Biol (Basel). 118: 71–77. PMID 15645675.
- Luo Y, Qiu J. Human parvovirus B19: a mechanistic overview of infection and DNA replication. Future Virol. 2015;10(2):155–167. doi:10.2217/fvl.14.103
- Landenberg et al. Human parvovirus B19 infection and antiphospholipid antibodies, 2006
- G. Siegl and P. Cassinotti, Parvoviruses Chapter 14, Topley and Wison's Microbiology and Microbial Infections, Vol. 1, Virology, 1998 pp. 261–280
- Molenaar-de Backer MW, Lukashov VV, van Binnendijk RS, Boot HJ, Zaaijer HL (2012). "Global co-existence of two evolutionary lineages of parvovirus B19 1a, different in genome-wide synonymous positions". PLOS ONE. 7 (8): e43206. Bibcode:2012PLoSO...743206M. doi:10.1371/journal.pone.0043206. PMC 3418230. PMID 22912828.
- Stamenković GG, Ćirković VS, Šiljić MM, Blagojević JV, Knežević AM, Joksić ID, Stanojević MP (2016). "Substitution rate and natural selection in parvovirus B19". Sci Rep. 6: 35759. Bibcode:2016NatSR...635759S. doi:10.1038/srep35759. PMC 5075947. PMID 27775080.
- Aslanidis et al. Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?, 2007.
- Mühlemann B, Margaryan A, Damgaard PB, Allentoft ME, Vinner L, Hansen AJ, Weber A, Bazaliiskii VI, Molak M, Arneborg J, Bogdanowicz W, Falys C, Sablin M, Smrčka V, Sten S, Tashbaeva K, Lynnerup N, Sikora M, Smith DJ, Fouchier RAM, Drosten C, Sjögren KG, Kristiansen K, Willerslev E, Jones TC (2018) Ancient human parvovirus B19 in Eurasia reveals its long-term association with humans. Proc Natl Acad Sci U S A
- Pattison JR, Patou G (1996). Baron S, et al. (eds.). Parvoviruses. In: Barron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN 978-0-9631172-1-2.
- Young NS, Brown KE (February 2004). "Parvovirus B19". N Engl J Med. 350 (6): 586–597. doi:10.1056/NEJMra030840. PMID 14762186.
- "Fifth Disease (for Parents)".
- Corcoran A, Doyle S (2004). "Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19" (PDF). J Med Microbiol. 53 (Pt 6): 459–75. doi:10.1099/jmm.0.05485-0. PMID 15150324.
- Lehmann HW, von Landenberg P, Modrow S (2003). "Parvovirus B19 infection and autoimmune disease". Autoimmun Rev. 2 (4): 218–223. doi:10.1016/S1568-9972(03)00014-4. PMID 12848949.
- ENDERS M; WEIDNER A; ENDERS G (2006). "Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany". Epidemiology and Infection. 135 (4): 563–569. doi:10.1017/S095026880600731X. PMC 2870617. PMID 17064457.
- Servey JT, Reamy BV, Hodge J (February 2007). "Clinical presentations of parvovirus B19 infection". Am Fam Physician. 75 (3): 373–376. PMID 17304869. Retrieved 6 November 2009.
- Ballou WR, Reed JL, Noble W, Young NS, Koenig S (2003). "Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1". J Infect Dis. 187 (4): 675–8. doi:10.1086/368382. PMID 12599085.
- Lamont RF, Sobel JD, Vaisbuch E, Kusanovic JP, Mazaki-Tovi S, Kim SK, Uldbjerg N, Romero R (January 2011). "Parvovirus B19 infection in human pregnancy". BJOG : An International Journal of Obstetrics and Gynaecology. 118 (2): 175–86. doi:10.1111/j.1471-0528.2010.02749.x. PMC 3059196. PMID 21040396.
- Santonja C, Nieto-González G, Santos-Briz Á, Gutiérrez Zufiaurre Mde L, Cerroni L, Kutzner H, Requena L (December 2011). "Immunohistochemical detection of parvovirus B19 in "gloves and socks" papular purpuric syndrome: direct evidence for viral endothelial involvement. Report of three cases and review of the literature". The American Journal of Dermatopathology. 33 (8): 790–5. doi:10.1097/DAD.0b013e318221bc41. PMID 22024574. S2CID 41097601.
- Doldan Silvero AM, Acevedo-Gadea CR, Pantanowitz L, Dezube BJ, Johari V (June 2009). "Images in HIV/AIDS. Unsuspected parvovirus B19 infection in a person with AIDS". The AIDS Reader. 19 (6): 225–227. PMID 19642240.
- Landenberg et al. Human parvovirus B19 infection and antiphospholipid antibodies , 2006.
- "Other Types of Arthritis". Arthritis Action UK. Arthritis Action. Archived from the original on 13 February 2016. Retrieved 16 October 2015.
- "Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection". J Rheumatol. 1996. pp. 112–9.
- Fjaerli, H. O.; Vogt, H.; Bruu, A. L. (1991). "Human parvovirus B19 as the cause of aplastic crisis in hereditary spherocytosis". Tidsskrift for den Norske Laegeforening. 111 (22): 2735–2737. PMID 1658972.
- Beland, S. S.; Daniel, G. K.; Menard, J. C.; Miller, N. M. (1997). "Aplastic crisis associated with parvovirus B19 in an adult with hereditary spherocytosis". The Journal of the Arkansas Medical Society. 94 (4): 163–164. PMID 9308316.
- Ergaz Z, Ornoy A (May 2006). "Parvovirus B19 in pregnancy". Reprod. Toxicol. 21 (4): 421–35. doi:10.1016/j.reprotox.2005.01.006. PMID 16580942.
- Nagel, Hélène T. C. MD; de Haan, Timo R. MD; Vandenbussche, Frank P. H. A. MD; Oepkes, Dick MD & Walther, Frans J. MD (2007). "Long-Term Outcome After Fetal Transfusion for Hydrops Associated With Parvovirus B19 Infection". Obstetrics & Gynecology. 109 (1): 42–47. doi:10.1097/01.AOG.0000249611.67873.94. PMID 17197586. S2CID 19731784.
- Bassols, A. C. (2008). "Parvovirus B19 and the New Century". Clinical Infectious Diseases. 46 (4): 537–539. doi:10.1086/526523. PMID 18194096.
- Katragadda, L.; Shahid, Z.; Restrepo, A.; Muzaffar, J.; Alapat, D.; Anaissie, E. (2013). "Preemptive intravenous immunoglobulin allows safe and timely administration of antineoplastic therapies in patients with multiple myeloma and parvovirus B19 disease". Transplant Infectious Disease. 15 (4): 354–60. doi:10.1111/tid.12067. PMID 23578205.
- Crabol, Y.; Terrier, B.; Rozenberg, F.; Pestre, V.; Legendre, C.; Hermine, O.; Montagnier-Petrissans, C.; Guillevin, L.; Mouthon, L.; Groupe d'experts de l'Assistance Publique-Hôpitaux de Paris; Loic, G.; Annette, B.; Alain, F.; Bertrand, F.; Bertrand, G.; Amelie, L.; Isabelle, L.; Catherine, M.-P.; Luc, M.; Eric, O.; Nathalie, P.; Helene, S.; Tarek, S.; Hopital Ambroise, P.; Jean-Marie, L. P.; Bruno, F.; Bernard, C.; Thomas, P.; Francois, D.; Loic, G.; et al. (2012). "Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature". Clinical Infectious Diseases. 56 (7): 968–977. doi:10.1093/cid/cis1046. PMID 23243178.
- Yang, S. H.; Lin, L. W.; Fang, Y. J.; Cheng, A. L.; Kuo, S. H. (2011). "Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma". Annals of Hematology. 91 (2): 291–294. doi:10.1007/s00277-011-1238-8. PMID 21538062. S2CID 6438572.
- Klepfish, A.; Rachmilevitch, E.; Schattner, A. (2006). "Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment". European Journal of Internal Medicine. 17 (7): 505–507. doi:10.1016/j.ejim.2006.05.002. PMID 17098597.
- Hartmann, J. T.; Meisinger, I.; Kröber, S. M.; Weisel, K.; Klingel, K.; Kanz, L. (2006). "Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma". Haematologica. 91 (12 Suppl): ECR49. PMID 17194655.
- Chandramouli S, Medina-Selby A, Coit D, Schaefer M, Spencer T, Brito LA, Zhang P, Otten G, Mandl CW, Mason PW, Dormitzer PR, Settembre EC (20 August 2013). "Generation of a parvovirus B19 vaccine candidate". Vaccine. 31 (37): 3872–8. doi:10.1016/j.vaccine.2013.06.062. PMID 23827313.